Search

Author/Creator Lindstrom, Beatriz

1. Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo‐controlled trial (CAPTIVATE). Issue 5 (5th February 2023)

Authors:
Chang, Lin; Cash, Brooks D.; Lembo, Anthony; Kunkel, David C.; English, Brett A.; Lindstrom, Beatriz; Gu, Guibao; Skare, Sharon; Gilder, Kye; Turner, Stewart; Cataldi, Fabio; Lipkis, Donald; Tack, Jan
Journal:
Neurogastroenterology & motility
Issue:
Volume 35:Issue 5(2023)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, reduces colitis-induced acute and chronic visceral hypersensitivity in rodents. Issue 1 (January 2022)

Authors:
Castro, Joel; Garcia-Caraballo, Sonia; Maddern, Jessica; Schober, Gudrun; Lumsden, Amanda; Harrington, Andrea; Schmiel, Shirdi; Lindstrom, Beatriz; Adams, John; Brierley, Stuart M.
Journal:
Pain
Issue:
Volume 163:Issue 1(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search